Surrogate end points for survival in the target treatment of advanced non-small-cell lung cancer with gefitinib or erlotinib

被引：0
|
作者：
Xiaoqin Li
Shan Liu
Hangang Gu
Deqiang Wang
机构：
[1] Affiliated Hospital of Jiangsu University,Cancer Therapy Center
[2] Affiliated Hospital of Jiangsu University,Research Room of Oncologic Emergency, Emergency Internal Medicine
来源：
Journal of Cancer Research and Clinical Oncology | 2012年 / 138卷
关键词：
Erlotinib; Gefitinib; Non-small-cell lung cancer; Median survival time;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1963 / 1969
页数：6
相关论文
共 50 条
  • [41] Erlotinib in patients with advanced non-small-cell lung cancer: impact of dose reductions and a novel surrogate marker
    Daniel Binder
    Ann-Christin Buckendahl
    Ralf-Harto Hübner
    Peter Schlattmann
    Bettina Temmesfeld-Wollbrück
    Thomas Beinert
    Norbert Suttorp
    [J]. Medical Oncology, 2012, 29 : 193 - 198
  • [42] Modeling Tumor Dynamics and Overall Survival in Advanced Non-Small-Cell Lung Cancer Treated with Erlotinib
    Suleiman, Ahmed Abbas
    Frechen, Sebastian
    Scheffler, Matthias
    Zander, Thomas
    Kahraman, Deniz
    Kobe, Carsten
    Wolf, JRgen
    Nogova, Lucia
    Fuhr, Uwe
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (01) : 84 - 92
  • [43] Optimizing response to gefitinib in the treatment of non-small-cell lung cancer
    Carotenuto, Pietro
    Roma, Cristin
    Rachiglio, Anna Maria
    Pasquale, Raffaella
    Franco, Renato
    Antinolfi, Giuseppe
    Piantedosi, Francovito
    Illiano, Alfonso
    Botti, Gerardo
    Morabito, Alessandro
    Normanno, Nicola
    De Luca, Antonella
    [J]. PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2011, 4 : 1 - 9
  • [44] APL during gefitinib treatment for non-small-cell lung cancer
    Uchida, A
    Matsuo, K
    Tanimoto, M
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (08): : 843 - 843
  • [45] Survival outcomes in patients with non-small-cell lung cancer treated with erlotinib
    McGrath, Alexandria C.
    Sandhu, Geeta
    Walpole, Euan
    McCaffrey, Elizabeth
    Hollingworth, Samantha A.
    [J]. ANTI-CANCER DRUGS, 2018, 29 (08) : 786 - 790
  • [46] Pulmonary Toxicities of Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer
    Hong, Dongsheng
    Zhang, Guobing
    Zhang, Xingguo
    Lian, Xingguang
    [J]. MEDICINE, 2016, 95 (09)
  • [47] Erlotinib as a salvage treatment for patients with advanced non-small cell lung cancer after failure of gefitinib treatment
    Song Zheng-bo
    Yu Yong-feng
    Chen Zhi-wei
    Lu Shun
    [J]. CHINESE MEDICAL JOURNAL, 2011, 124 (15) : 2279 - 2283
  • [48] Gefitinib ('Iressa'): a new therapy for advanced non-small-cell lung cancer
    Reck, M
    Gatzemeier, U
    [J]. RESPIRATORY MEDICINE, 2005, 99 (03) : 298 - 307
  • [49] Gefitinib Monotherapy in Advanced non-small-cell Lung Cancer: A Retrospective Analysis
    Shrestha, S.
    Joshi, P.
    [J]. JOURNAL OF NEPAL MEDICAL ASSOCIATION, 2012, 52 (02) : 66 - 71
  • [50] Gefitinib in pretreated advanced or metastatic non-small-cell lung cancer patients
    Garde, J
    Blasco, A
    Camps, C
    Juarez, A
    Caballero, C
    Sirera, R
    Bayo, R
    Ponce, R
    Berrocal, A
    Jackobs, J
    [J]. LUNG CANCER, 2004, 45 : S80 - S80
12345